Log in

Relevant bibliographies by topics / Acid peptic disorders / Journal articles

To see the other types of publications on this topic, follow the link: Acid peptic disorders.

Journal articles on the topic 'Acid peptic disorders'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Acid peptic disorders.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kale-Pradhan, Pramodini B., Heather K. Landry, and William T. Sypula. "Esomeprazole for Acid Peptic Disorders." Annals of Pharmacotherapy 36, no. 4 (2002): 655–63. http://dx.doi.org/10.1345/aph.1a104.

Full text

Abstract:

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of esomeprazole, a new proton-pump inhibitor (PPI). DATA SOURCES: A MEDLINE search (1966–March 2001) was conducted for relevant literature using the terms esomeprazole, Nexium, and H199/18. Abstracts from the XXXII Nordic Meeting of Gastroenterology and journal articles provided by AstraZeneca were reviewed. STUDY SELECTION AND DATA EXTRACTION: All available studies on the pharmacology, pharmacokinetics, clinical efficacy, and safety of esomeprazole were reviewed. DATA SYNTHESIS: Esomeprazole is a new PPI an

APA, Harvard, Vancouver, ISO, and other styles

2

Kuwayama, Hajime. "ADVANCES IN TREATING ACID PEPTIC DISORDERS." Journal of Gastroenterology and Hepatology 15, no. 12 (2000): H31. http://dx.doi.org/10.1046/j.1440-1746.2000.015012h31.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Nasir, M., and AFM M. Rahman. "Proton Pump Inhibitors : The Controversies to Consider." Journal of Medical Science & Research 19, Number 2 (2012): 33–37. http://dx.doi.org/10.47648/jmsr.2012.v1902.06.

Full text

Abstract:

Heartburn is ailing the masses. By one estimate. 20% of the Western population experiences acid reflux at least once a week and shelling out buckets of cash S25.6 billion worldwide in 2008 to alleviate those hot, sour. acidic pains in the chest. Proton pump inhibitors (PPIs) am one of the most commonly prescribed classes of medications in the primary care setting and are considered a major advance in the treatment of acid-peptic diseases. Since the introduction of omeprazok in 1989. several other PPIs have become available in combating various acid-peptic disorders, including gastroesophageal

APA, Harvard, Vancouver, ISO, and other styles

4

Nasir, M., and AFM M. Rahman. "Proton Pump Inhibitors : The Controversies to Consider." Journal of Medical Science & Research 19, Number 2 (2012): 33–37. http://dx.doi.org/10.47648/jmsr.2012.v1902.07.

Full text

Abstract:

Heartburn is ailing the masses. By one estimate. 20% of the Western population experiences acid reflux at least once a week and shelling out buckets of cash S25.6 billion worldwide in 2008 to alleviate those hot, sour. acidic pains in the chest. Proton pump inhibitors (PPIs) am one of the most commonly prescribed classes of medications in the primary care setting and are considered a major advance in the treatment of acid-peptic diseases. Since the introduction of omeprazok in 1989. several other PPIs have become available in combating various acid-peptic disorders, including gastroesophageal

APA, Harvard, Vancouver, ISO, and other styles

5

Gustavsson, S., and L. Engstrand. "Future Strategies in Acid-peptic Disorders: Concluding Remarks." Scandinavian Journal of Gastroenterology 23, sup142 (1988): 114–16. http://dx.doi.org/10.3109/00365528809091725.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Saltiel, Emmanuel. "Peptic Acid Disorders: Developing a Disease Management Program." Journal of Managed Care Pharmacy 2, no. 5 (1996): 569–75. http://dx.doi.org/10.18553/jmcp.1996.2.5.569.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Parthasarathy, Srinivasan. "Vonoprazan – A New Drug for Acid Peptic Disorders." SBV Journal of Basic, Clinical and Applied Health Science 7, no. 3 (2024): 103–4. http://dx.doi.org/10.4103/sbvj.sbvj_42_24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

CLEARFIELD, H. R. "Challenges in acid/peptic disorders: a symposium overview." Alimentary Pharmacology & Therapeutics 5 (March 31, 2007): 1–4. http://dx.doi.org/10.1111/j.1365-2036.1991.tb00743.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

LEWIS, J. H. "Idiopathic gastric acid hypersecretion: treatment implications for refractory acid/peptic disorders." Alimentary Pharmacology & Therapeutics 5 (March 31, 2007): 15–24. http://dx.doi.org/10.1111/j.1365-2036.1991.tb00745.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Islam, M. M. Shahin Ul. "“Potassium Competitive Acid Blocker”- new Weapon to Combat Acid Peptic Disorders." Bangabandhu Sheikh Mujib Medical College Journal 2, no. 2 (2023): 72–73. http://dx.doi.org/10.3329/bsmmcj.v2i2.69830.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Yacoub, WR, ABR Thomson, P. Hooper, and LD Jewell. "Lack of Effect of H2-Receptor Antagonists and Antacids on the Gastric and Duodenal Gastrin-, Somatostatin- and Serotonin-Producing Cells in Patients with Acid Peptic Disorders." Canadian Journal of Gastroenterology 10, no. 4 (1996): 255–59. http://dx.doi.org/10.1155/1996/910703.

Full text

Abstract:

Standard therapeutic approaches to acid peptic disorders have dealt with neutralizing or inhibiting aggressive factors and/or bolstering defensive factors. Gastric and duodenal mucosal biopsies were examined from 90 patients with various acid peptic disorders, as follows: reflux esophagitis (n=24), gastric ulcer (n=13), duodenal ulcer (n=47) and nonulcer dyspepsia (n=6). Seven patients with minimal dyspeptic symptoms and an endoscopically and histologically normal stomach and duodenum served as controls. Immunoperoxidase staining for gastrin-producing G cells, somatostatin-producing D cells an

APA, Harvard, Vancouver, ISO, and other styles

12

Eswaran, Sheila, and Michael A. Roy. "Medical Management of Acid-Peptic Disorders of the Stomach." Surgical Clinics of North America 85, no. 5 (2005): 895–906. http://dx.doi.org/10.1016/j.suc.2005.05.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Beck, Jean. "Efficacy of Esomeprazole in Patients With Acid-Peptic Disorders." Gastroenterology Nursing 27, no. 2 (2004): 44–49. http://dx.doi.org/10.1097/00001610-200403000-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Thapa, Rashmi, Mohir Pokharel, Saroj Paudel, et al. "Acid Peptic Disease among Patients with Acute Abdomen Visiting the Department of Emergency Medicine in a Tertiary Care Centre." Journal of Nepal Medical Association 61, no. 264 (2023): 636–38. http://dx.doi.org/10.31729/jnma.8228.

Full text

Abstract:

Introduction: Acid peptic disease is caused by excessive acid secretion or weakened mucosal defense. Symptoms include epigastric pain, bloating, and nausea. Factors like gastric acid, Helicobacter pylori infection, alcohol consumption, smoking, and stress contribute to peptic ulcers. Imbalances between offensive and defensive factors can lead to ulcers. Acid-related disorders impact the quality of life and mortality. Accurate diagnosis and prompt treatment are vital. This study aimed to find out the prevalence of acid peptic disease among patients with acute abdomen in the Department of Emerge

APA, Harvard, Vancouver, ISO, and other styles

15

Garnett, William R., and Susan M. Garabedian‐Ruffalo. "Identification, Diagnosis, and Treatment of Acid‐Related Diseases in the Elderly: Implications for Long‐Term Care." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 17, no. 5 (1997): 938–58. http://dx.doi.org/10.1002/j.1875-9114.1997.tb03784.x.

Full text

Abstract:

Acid‐related disorders such as peptic ulcer disease and gastroesophageal reflux disease occur frequently in the elderly and are associated with a high frequency of morbidity and mortality. The proton pump inhibitors lansoprazole and omeprazole produce faster rates of healing and greater symptomatic relief in patients with acid‐related disorders than histamine2‐receptor antagonists, are well tolerated, and are associated with few adverse events. Compared with omeprazole, which interacts with diazepam, warfarin, and phenytoin, lansoprazole produces only a minor increase in theophylline clearance

APA, Harvard, Vancouver, ISO, and other styles

16

Thomson, ABR. "Summary of an International and a Regional Symposium: Acid-Related Diseases - Improving Treatment Options." Canadian Journal of Gastroenterology 6, no. 4 (1992): 195–200. http://dx.doi.org/10.1155/1992/131453.

Full text

Abstract:

The author examines the clinical impact of findings from a key international workshop on acid peptic disorders, “Appropriate acid suppression for the healing of acid-related diseases,” and from an important meeting which summarized results of a cross-Canada study of the symptomatic treatment of dyspepsia due to esophagitis and duodenal ulcer disease.

APA, Harvard, Vancouver, ISO, and other styles

17

Segal, R. "Cost of acid peptic disorders in a managed-care organization." Clinical Therapeutics 18, no. 2 (1996): 319–33. http://dx.doi.org/10.1016/s0149-2918(96)80013-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Blum, Robert A. "Lansoprazole and omeprazole in the treatment of acid peptic disorders." American Journal of Health-System Pharmacy 53, no. 12 (1996): 1401–15. http://dx.doi.org/10.1093/ajhp/53.12.1401.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Yacoub, WR, ABR Thomson, RW Sherbaniuk, P. Hooper, and LD Jewell. "Positive Correlation between Normal Serum Gastrin Concentrations and Antral and Duodenal G Cells." Canadian Journal of Gastroenterology 8, no. 4 (1994): 235–38. http://dx.doi.org/10.1155/1994/151096.

Full text

Abstract:

It is controversial whether there is a correlation between serum gastrin concentrations and the density of G cells in the antral or duodenal mucosa. In this study, endoscopically obtained antral and duodenal biopsies were stained immunocytochemically for gastrin and the G cells quantitated using an MOP Videoplan computer image analysis system. Studies were performed in 20 patients with acid-peptic disorders (gastric ulcer, n=5; duodenal ulcer, n=10; reflux esophagitis, n=4; and nonulcer dyspepsia, n=1). Correlations between antral and duodenal G cell densities, and basal- and food-stimulated s

APA, Harvard, Vancouver, ISO, and other styles

20

El-Omar, E. M. "The clinician's guide to acid/peptic disorders and motility disorders of the gastrointestinal tract." Gut 56, no. 10 (2007): 1487. http://dx.doi.org/10.1136/gut.2007.121418.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Ambalavanar, DC, and G. Pradeepkumar. "CLO test positivity in patients with acid-peptic disorders in Jaffna." Ceylon Medical Journal 46, no. 4 (2014): 158. http://dx.doi.org/10.4038/cmj.v46i4.6473.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

P R, Chetan, Madhusudhan A, Naveen P R, and Prashanth H L. "PREVALENCE OF HELICOBACTER PYLORI INFECTION IN PATIENTS WITH ACID PEPTIC DISORDERS." Journal of Evolution of Medical and Dental Sciences 3, no. 32 (2014): 8735–40. http://dx.doi.org/10.14260/jemds/2014/3115.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Souza, Rhonda F., Joel H. Rubenstein, John Y. Kao, and Ikuo Hirano. "Contributions From Gastroenterology: Acid Peptic Disorders, Barrett’s Esophagus and Eosinophilic Esophagitis." Gastroenterology 154, no. 5 (2018): 1209–14. http://dx.doi.org/10.1053/j.gastro.2017.12.023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Bhagora, Rinku, Sakshi Chaurasia, Shilpi Singh, and Megha Goswami. "Acid Peptic Disorders In Sickle Cell Disease: Incidence And Management Strategies." Research Journal Of Medical Sciences 18, no. 6 (2024): 537–40. http://dx.doi.org/10.36478/makrjms.2024.6.537.540.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Alfahad, Mohanad, Mahmood H. M. Jasim, Mohannad E. Qazzaz, Fawaz A. Alassaf, and Mohammed N. Abed. "Proton pump inhibitors and peptic ulcer management: Antioxidant mechanisms." Journal of Drug Delivery and Therapeutics 11, no. 4-S (2021): 242–46. http://dx.doi.org/10.22270/jddt.v11i4-s.4955.

Full text

Abstract:

Peptic ulcer (P.U.) is the gastrointestinal tract's most frequent disorder affecting mainly the stomach and duodenum. Surgical intervention, ingested materials and microbial infections may trigger inflammation that further predispose to oxidative stress. Proton pump inhibitors (PPIs) are group of compounds established for suppressions of gastric acid secretions profoundly and permanently over a reasonably long period of time. Oxidative stress has been shown to be involved in the pathophysiology of various diseases and disorders, including P.U. Particularly when H. pylori infection accompanies

APA, Harvard, Vancouver, ISO, and other styles

26

Mezoff, Adam G., and William F. Balistreri. "Peptic Ulcer Disease in Children." Pediatrics In Review 16, no. 7 (1995): 257–65. http://dx.doi.org/10.1542/pir.16.7.257.

Full text

Abstract:

The term peptic ulcer disease describes a group of disorders, rather than a single pathologic process. It is recognized increasingly in children, often with long-term ramifications. In the past decade, management of patients who have peptic ulcer disease has changed dramatically. Antacid therapy has given way to treatment with histamine (H2) receptor antagonists, a new class of pharmacologic agents that has fostered a billion dollar industry. Other modalities of treatment have been developed as well, such as cytoprotective agents (sucralfate) and proton pump inhibitors (omeprazole), which are

APA, Harvard, Vancouver, ISO, and other styles

27

Shin, Cheol Min. "Acid Suppressive Drugs." Korean Journal of Helicobacter and Upper Gastrointestinal Research 22, no. 2 (2022): 119–30. http://dx.doi.org/10.7704/kjhugr.2022.0016.

Full text

Abstract:

Histamine H<sub>2</sub> receptor antagonists (H<sub>2</sub>RAs) suppress gastric acid production by blocking H<sub>2</sub> receptors in parietal cells. Studies have shown that proton pump inhibitors (PPIs) are superior to H<sub>2</sub>RAs as a treatment for acid-related disorders, such as peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). PPIs reduce gastric acid production by irreversibly inhibiting the H<sup>+</sup>/K<sup>+</sup> ATPase pump, and they also increase gastric emptying. Although PPIs have

APA, Harvard, Vancouver, ISO, and other styles

28

Weart, C. Wayne, and Harry Leider. "Opportunities for Pharmacists to Aid in the Management of Acid-Peptic Disorders." Disease Management & Health Outcomes 12, no. 4 (2004): 239–47. http://dx.doi.org/10.2165/00115677-200412040-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Lampkin, Thomas A., Daniele Ouellet, Lawrence J. Hak, and George E. Dukes. "Omeprazole: A Novel Antisecretory Agent for the Treatment of Acid-Peptic Disorders." DICP 24, no. 4 (1990): 393–402. http://dx.doi.org/10.1177/106002809002400411.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Jain, Kishor S., Anamik K. Shah, Jitender Bariwal, et al. "Recent advances in proton pump inhibitors and management of acid-peptic disorders." Bioorganic & Medicinal Chemistry 15, no. 3 (2007): 1181–205. http://dx.doi.org/10.1016/j.bmc.2006.07.068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Cho, Mun Young, and Yu Kyung Cho. "Role of Potassium-competitive Acid Blockers in the Treatment of Gastric Acid-related Disorders." Korean Journal of Helicobacter and Upper Gastrointestinal Research 23, no. 3 (2023): 167–73. http://dx.doi.org/10.7704/kjhugr.2023.0043.

Full text

Abstract:

Owing to their superior pharmacokinetic and pharmacodynamic profiles, potassium-competitive acid blockers (P-CABs) score over proton pump inhibitors (PPIs) in the treatment of gastric acid-related disorders and may provide clinical benefit in the management of these conditions. Previous studies have compared P-CABs with PPIs for treatment of gastric acid-related disorders, and current data show that P-CABs are non-inferior to PPIs in the treatment of erosive esophagitis and as maintenance therapy. P-CABs are useful for effective healing and as maintenance medications in patients with severe es

APA, Harvard, Vancouver, ISO, and other styles

32

Ambica, Prasad M., D.V. Ramanjaneyuly, Sharlet E. Sony, et al. "Etiology, causes, symptoms, diagnosis and treatment regarding Pharmacotherapy for Stomach Disorders." Research and Reviews: Journal of Wound, Ostomy and Continence Nursing 2, no. 2 (2024): 39–48. https://doi.org/10.5281/zenodo.13347632.

Full text

Abstract:

<em>The stomach, a key component of the digestive system, is prone to various disorders that can influence an individual's well-being in a significant manner. From acid-related conditions like gastritis and peptic ulcers to more complex issues such as gastro paresis and stomach cancer, effective pharmacotherapy plays an important role in managing these disorders. In this article, we will provide information regarding the treatment of stomach diseases in humans, highlighting their mechanisms of action as well as clinical applications.</em>

APA, Harvard, Vancouver, ISO, and other styles

33

T., Rama Rao, Akshaya D., Sravya G., and Kaushik T. "VONOPRAZAN: An Innovative Approach to Acid-Related Disorders." International Journal of Innovative Science and Research Technology (IJISRT) 10, no. 2 (2025): 905–8. https://doi.org/10.5281/zenodo.14937088.

Full text

Abstract:

A frequent condition of the upper gastrointestinal system, gastro-esophageal reflux extermination causes the contents of the stomach to reflux into the esophagus. Less frequent reflux symptoms include heartburn, dysphagia, belching, hiccups, nausea, and vomiting. In order to treat and prevent acid-related conditions such as erosive esophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro-esophageal reflux, reflux esophagitis, and Helicobacter pylori eradication, vonoprazan, an oral bioavailable P-CAB, is being developed. 10 mg and 20 mg are among the dosages. Women who are or may becom

APA, Harvard, Vancouver, ISO, and other styles

34

Rai, Ramesh Roop, A. Gangadhar, and Mayur M. Mayabhate. "Clinical profiling of patients with Acid Peptic Disorders (APD) in India: a cross-sectional survey of clinicians." International Journal of Basic & Clinical Pharmacology 6, no. 1 (2016): 194. http://dx.doi.org/10.18203/2319-2003.ijbcp20164779.

Full text

Abstract:

Background: Acid peptic disorders (APD) which include GERD and peptic ulcer disease (PUD) are common conditions reported in daily clinical practice. This survey aimed to understand the epidemiology, clinical presentation and associated overlapping comorbidities in Indian patients with APD.Methods: This was an interview based cross-sectional survey of 1000 clinicians (specialist gastroenterologists and non-specialists) across India who treated patients of APD in their practice. Information related to patient demographics, diagnosis and clinical presentation (common symptoms and their duration,

APA, Harvard, Vancouver, ISO, and other styles

35

&NA;. "Pharmacists have many opportunities to aid in the management of acid-peptic disorders." Drugs & Therapy Perspectives 21, no. 5 (2005): 23–26. http://dx.doi.org/10.2165/00042310-200521050-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Periyasamy, Manivannan, Suresh Ramasamy, and Mahalakshmi V. "IN-VITRO EVALUATION OF THE ANTIULCER POTENTIAL OF BAVANA KADUKKAI MATHIRAI." International Journal of Research in Ayurveda and Pharmacy 16, no. 2 (2025): 247–50. https://doi.org/10.7897/2277-4343.16280.

Full text

Abstract:

The Siddha system of medicine, widely practised in Southern India, includes numerous formulations for treating various ailments. Bavana Kadukkai Mathirai (BVK) is a traditional Siddha formulation for managing Gunmam (Peptic ulcer disease). Peptic ulcers occur due to an imbalance between aggressive factors like gastric acid, pepsin, and H. pylori and defensive factors such as mucin, prostaglandins, and bicarbonate. This study evaluates the acid- neutralizing capacity of BVK using an in-vitro method. The formulation was prepared using key herbal ingredients, including Terminalia chebula, Zingibe

APA, Harvard, Vancouver, ISO, and other styles

37

Abdel‐Aziz, Yousef, David C. Metz, and Colin W. Howden. "Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders." Alimentary Pharmacology & Therapeutics 53, no. 7 (2021): 794–809. http://dx.doi.org/10.1111/apt.16295.

Full text

Abstract:

SummaryBackgroundPotassium‐competitive acid blockers (P‐CABs) are a novel group of acid‐suppressing medicines for the management of acid‐related disorders.AimsTo review published clinical pharmacology studies and clinical trials of P‐CABs.MethodsWe conducted a comprehensive literature search including Medline (PubMed), EMBASE, Web of Science and the Cochrane Library from inception until November 2020, for studies of the clinical pharmacology of P‐CABs and relevant clinical trials of those that are currently licensed or in development.ResultsMost publications concerned vonoprazan, which forms t

APA, Harvard, Vancouver, ISO, and other styles

38

Parveen, Tasrina, Monisha Nath, Maitri Chakraborty, and Nirban Roy. "QUALITY OF LIFE OF THE PEPTIC ULCER PATIENT." International Journal of Advanced Research 9, no. 06 (2021): 480–91. http://dx.doi.org/10.21474/ijar01/13037.

Full text

Abstract:

New generation, which has been brought up in a world where geographical boundaries are no constraintis ready to try new recipes from across the world. The trend is catching up with the older generation also. But all such foods are not safe and can cause PUD. Various studies have shown detrimental effects of such so called junk foods on health of young adult males. Nowadays junk food has become the main attraction for the young generation as it also comes to western culture. The boys specially, who spend most of their time outside of their home, mainly eats unhygienic junk foods. For that reaso

APA, Harvard, Vancouver, ISO, and other styles

39

Díaz-Ordóñez, Lorena, Diana Ramírez-Montaño, Estephania Candelo, et al. "Evaluation of CYP2C19 Gene Polymorphisms in Patients with Acid Peptic Disorders Treated with Esomeprazole." Pharmacogenomics and Personalized Medicine Volume 14 (April 2021): 509–20. http://dx.doi.org/10.2147/pgpm.s285144.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Bhalerao, SupriyaSudhakar, PoonamAshish Gupte, MadhaviPrabhakar Mahajan, et al. "Efficacy and acceptability of pomegranate effervescent granules in patients suffering from acid peptic disorders." Indian Journal of Pharmacology 54, no. 1 (2022): 7. http://dx.doi.org/10.4103/ijp.ijp_914_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Venkatesan, H. "Retrospective Analytical Case Series Study on the Acid Peptic Disorders treated with Homoeopathic Medications." Research Journal of Pharmacology and Pharmacodynamics 12, no. 2 (2020): 97. http://dx.doi.org/10.5958/2321-5836.2020.00019.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Yacoub, WR, ABR Thomson, P. Hooper, and LD Jewell. "Immunocytochemical and Morphometric Studies of Gastrin-, Somatostatin- and Serotonin-Producing Cells in the Stomach and Duodenum of Patients with Acid Peptic Disorders." Canadian Journal of Gastroenterology 10, no. 6 (1996): 395–400. http://dx.doi.org/10.1155/1996/245908.

Full text

Abstract:

Gastric and duodenal biopsies from 90 patients with various acid peptic disorders - reflux esophagitis (n=24), gastric ulcer (n=13), duodenal ulcer (n=47) and nonulcer dyspepsia (n=6) - were examined. Seven patients with minimal dyspeptic symptoms and an endoscopically and histologically normal stomach and duodenum served as controls. Immunoperoxidase staining for gastrin-producing G cells, somatostatin-producing D cells and serotonin-producing EC cells was carried out on fundic, antral and duodenal biopsies, and was quantified using a Zeiss MOP Videoplan using the peroxidase-antiperoxidase te

APA, Harvard, Vancouver, ISO, and other styles

43

Sitharthan, R. "Homoeopathy in Treatment of Gastro Intestinal Disorders - A Retrospective Study." Advancements in Homeopathic Research 8, no. 1 (2023): 41–46. http://dx.doi.org/10.48165/ahr.2023.8.1.4.

Full text

Abstract:

Introduction: Acid peptic disorder (APD) is a condition which includes peptic ulcer and gastro esophageal reflux disease (GERD). The highest prevalence rate of gastric disorders had been found out between ages 45-50. Dyspepsia is a term used for reduced digestion or indigestion. GERD is referred to as condition where there is regurgitation of stomach contents to the esophagus. Around 58.7% of peoples are having acid regurgitation or heart burn yearly once and 19.8% weekly once. Worldwide functional gastrointestinal disorder are commonest now a days, Irritable Bowel Syndrome (IBS) is also one a

APA, Harvard, Vancouver, ISO, and other styles

44

Prasad VG, Mohan, Lynne V. McFarland, Hemant P. Thacker, Rajesh Puri, and Parimal S. Lawate. "Efficacy and Safety of Omeprazole for the Treatment of Acid Peptic Disorders: A Systematic Review and Meta-Analysis." International Journal of Clinical Practice 2024 (March 28, 2024): 1–13. http://dx.doi.org/10.1155/2024/9990554.

Full text

Abstract:

Background Aim. To compare the efficacy of omeprazole to other proton-pump inhibitors (PPIs) or placebo for the treatment of acid peptic disorders (APDs) using a comprehensive literature search including hard-to-access journals and non-English articles. Methods. PubMed, Google Scholar, and China National Knowledge Infrastructure were searched (from inception to March 2023) for trials comparing omeprazole to other types of PPIs or placebo for the treatment APD. Efficacy was analyzed separately for erosive diseases and nonerosive diseases. Primary outcomes included improvement of APD symptoms an

APA, Harvard, Vancouver, ISO, and other styles

45

Upadhyay, Rajesh, N. K. Soni, Agam Vora, et al. "Association of Physicians of India Consensus Recommendations for Vonoprazan in Management of Acid Peptic Disorders." Journal of The Association of Physicians of India 73, no. 2 (2025): 68–77. https://doi.org/10.59556/japi.73.0844.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Mahesh, K. Goenka1 Kranthi Kiran Pebbili2 Shashank Desai3 Seema Bhagat2 Arti Sanghavi2 Sagar Katare2 Bhavesh Kotak2 Sunil Kumar Yadav Yadagiri2*. "Effectiveness and Satisfaction With Rabeprazole in Acid Peptic Disorders: Insights From Real World Observational Study, Power 2.0." International Journal of Gastroenterology and Hepatology 4, no. 1 (2025): 1–15. https://doi.org/10.5281/zenodo.15031099.

Full text

Abstract:

<strong>Introduction:</strong> Acid peptic disorders (APDs), including gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD), are prevalent conditions that significantly impair quality of life. Proton pump inhibitors (PPIs) are a cornerstone of APD management, but variability in their effectiveness necessitates evaluation, especially in the Indian context, due to lack of data. <strong>Methods:</strong><strong> </strong>The POWER 2.0 study is a multicenter, prospective, observational, non-interventional study that enrolled patients with APDs under routine clinical practice, incl

APA, Harvard, Vancouver, ISO, and other styles

47

Namikawa, Ken, and Einar Stefan Björnsson. "Rebound Acid Hypersecretion after Withdrawal of Long-Term Proton Pump Inhibitor (PPI) Treatment—Are PPIs Addictive?" International Journal of Molecular Sciences 25, no. 10 (2024): 5459. http://dx.doi.org/10.3390/ijms25105459.

Full text

Abstract:

Proton pump inhibitors (PPIs) are widely used in the long-term treatment of gastroesophageal reflux disease (GERD) and other upper gastrointestinal disorders, such as the healing of peptic ulcers and/or prophylactic treatment of peptic ulcers. PPIs are also widely used as symptomatic treatment in patients with functional dyspepsia. One of the adverse effects of the long-term use of PPI is rebound acid hypersecretion (RAHS), which can occur after the withdrawal of PPI therapy due to a compensatory increase in gastric acid production. Mechanisms of the RAHS have been well established. Studies ha

APA, Harvard, Vancouver, ISO, and other styles

48

Sarma, Usha, and Upasana Kalita. "Histopathological Study of Gastroduodenal Biopsies and to See the Prevalence of Helicobacter Pylori with the Help of Special Stains in Selected Cases in North East India- A Cross Sectional Study in a Tertiary Care Centre." Asian Pacific Journal of Cancer Biology 9, no. 4 (2024): 515–20. https://doi.org/10.31557/apjcb.2024.9.4.515-520.

Full text

Abstract:

Background: Acid peptic disease (APD), including gastric ulcers, duodenal ulcers, and gastro esophageal reflux disease is a common disorder of the gastrointestinal region, the pathogenesis of which involves an imbalance between acid secretion and gastric mucosal defenses. Acid peptic diseases mostly affect the esophagus, stomach, and duodenum. The imbalance could be caused by factors such as H pylori infection and acid secretory abnormalities in APD. Helicobacter pylori infection is a factor in 85% to 100% of duodenal ulcers and 70% to 90% of gastric ulcers. Besides, malignancies are also fair

APA, Harvard, Vancouver, ISO, and other styles

49

Prasad, Varpe*. "To In Vitro Assessment and Evaluation Liquorice Root Extract for Antacid Activity." International Journal of Pharmaceutical Sciences 3, no. 6 (2025): 738–47. https://doi.org/10.5281/zenodo.15596075.

Full text

Abstract:

Gastroesophageal reflux disease and peptic ulcers are common gastrointestinal disorders often treated with synthetic antacids. However, prolonged use of these agents can lead to adverse effects, prompting the search for safer, plant-based alternatives. In this study, the in vitro antacid activity of liquorice (Glycyrrhiza glabra) root extract was evaluated using a simulated gastric acid neutralization model. The extract was prepared using hydroalcoholic solvent extraction and subjected to phytochemical screening, revealing the presence of flavonoids, glycyrrhizin, and saponins—compounds

APA, Harvard, Vancouver, ISO, and other styles

50

Karan, Agale*1 Neha Said2 Vishal Madankar3. "Formulation and Evaluation of Omeprazole Floating Tablet for The Treatment of Peptic Ulcer." International Journal of Scientific Research and Technology 2, no. 6 (2025): 33–40. https://doi.org/10.5281/zenodo.15568974.

Full text

Abstract:

Peptic ulcers, Zollinger-Ellison syndrome, and acid-related gastrointestinal illnesses including Gastroesophageal Reflux Disease (GERD) can all be effectively treated with omeprazole, a popular proton pump inhibitor (PPI). Omeprazole's traditional formulation, however, has drawbacks including low bioavailability and quick stomach emptying, which lowers its therapeutic effectiveness. The creation of omeprazole floating tablets has shown promise as a solution to these issues. By providing extended gastric retention and improving drug release at the site of action, these tablets are made to float

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!